← SynDRA
LEVOBUNOLOL
SynDRA canonical compound SYN0023489 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | ADRB2 |
| Mechanism of action | Adrenergic receptor antagonist |
| Indication | glaucoma | ocular hypertension |
| Disease area | ophthalmology |
All known targets
- ADRB1
- ADRB2
- ADRB3
- Adrb3
- HTR1A
- Htr1a
- SIGMAR1
- SLC6A4
Mechanisms of action (all sources)
- Adrenergic receptor antagonist
- ADRB1 ANTAGONIST
- Beta-1 adrenergic receptor antagonist
- ADRB2 ANTAGONIST
- Beta-2 adrenergic receptor antagonist
Drug classes
- Adrenergic beta-Antagonists
- beta-Adrenergic Blocker
- Adrenergic Agents
- Adrenergic Antagonists
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sympatholytics
ATC classes
- S01E · ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Cross-references
Synonyms
- levobunolol hydrochloride
- levobunolol HCl
- betagan
- Bunolol, (-)-
- Bunolol, (s)-
- Akbeta
- Betagan
- Levobunololum
- Levobunolol HCl
- Betegan (TN)
- Levobunolol (INN)
- Levobunolol [INN:BAN]
- Levobunololum [INN-Latin]
- Liquifilm (TN)
- W-6412A
- W-7000A
- AK-Beta (TN)
- (-)-Bunolol
- (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone
- 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
- 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
- (S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydronaphthalen-1(2H)-one
- CHEBI:6438
- G6317AOI7K
- LEVOBUNOLOL [INN]
- l-Bunolol
- 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-one
- CCRIS 4375
- NCGC00016801-01
- CAS-27912-14-7
- liquifilm
- UNII-G6317AOI7K
- (-)-Levobunolol hydrochloride
- beta-site
- Ak-beta
- W-6421A
- BRN 1887243
Reported adverse events
- Bradycardia
- Bronchospasm
- Depression
- Headache
- Hypersensitivity
- Nausea
Look up LEVOBUNOLOL in the interactive SynDRA portal →